- Home
- BGM
as 11-14-2024 4:00pm EST
Stocks
BGM Group Ltd formerly, Qilian International Holding Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium.
| Founded: | 2019 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 52.8M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 18.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.77 - $8.96 | Next Earning Date: | 08-14-2024 |
| Revenue: | $29,870,461 | Revenue Growth: | -51.77% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest QILIAN INTERNATIONAL HLDG GROUP LTD News
BGM Breaking Stock News: Dive into BGM Ticker-Specific Updates for Smart Investing
Compare BGM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BGM QILIAN INTERNATIONAL HLDG GROUP LTD - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.